Baader Bank Aktiengesellschaft Acquires 1,001 Shares of Eli Lilly and Company (NYSE:LLY)

Key Points

• Baader Bank Aktiengesellschaft increased its holdings in Eli Lilly and Company by 23.3%, acquiring an additional 1,001 shares to total 5,291 shares valued at approximately $4.24 million.
• Analysts have issued mixed ratings on Eli Lilly, with updates including a price target increase from Guggenheim to $942 and a downgrade from HSBC to $700.
• Eli Lilly recently declared a quarterly dividend of $1.50, reflecting a 0.79% dividend yield and a payout ratio of 48.82%.

Baader Bank Aktiengesellschaft raised its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 23.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,291 shares of the company's stock after purchasing an additional 1,001 shares during the quarter. Baader Bank Aktiengesellschaft's holdings in Eli Lilly and Company were worth $4,238,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in LLY. WestEnd Advisors LLC increased its position in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares during the last quarter. Citizens National Bank Trust Department boosted its holdings in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after acquiring an additional 27 shares during the period. Financial Gravity Asset Management Inc. bought a new stake in Eli Lilly and Company during the first quarter valued at about $40,000. Mascagni Wealth Management Inc. bought a new stake in Eli Lilly and Company during the fourth quarter valued at about $43,000. Finally, O Brien Wealth Partners LLC boosted its holdings in Eli Lilly and Company by 25.5% during the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after acquiring an additional 12 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on LLY. Guggenheim upped their price target on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the company a "buy" rating in a report on Friday, July 11th. Cantor Fitzgerald began coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price target for the company. Morgan Stanley restated an "overweight" rating and set a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Wall Street Zen upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday. Finally, HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their target price for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $1,012.56.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded down $3.19 during midday trading on Wednesday, reaching $759.76. The company had a trading volume of 4,331,834 shares, compared to its average volume of 2,949,040. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $720.05 billion, a price-to-earnings ratio of 61.82, a price-to-earnings-growth ratio of 1.08 and a beta of 0.40. The stock has a fifty day simple moving average of $774.07 and a 200 day simple moving average of $800.13. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The company had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. During the same period in the prior year, the business earned $2.58 EPS. The business's revenue for the quarter was up 45.2% on a year-over-year basis. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.79%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.